Business Description
Compare
Compare
Traded in other countries / regions
543635.India IPO Date
2022-10-19Description
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.1 | |||||
| Equity-to-Asset | 0.52 | |||||
| Debt-to-Equity | 0.61 | |||||
| Debt-to-EBITDA | 3.16 | |||||
| Interest Coverage | 1.3 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 3.13 | |||||
| Beneish M-Score | -2.63 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 38.4 | |||||
| 3-Year EBITDA Growth Rate | 27.6 | |||||
| 3-Year EPS without NRI Growth Rate | -58.6 | |||||
| 3-Year Book Growth Rate | 21.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 174.79 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 14.37 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 10.54 | |||||
| 9-Day RSI | 21.02 | |||||
| 14-Day RSI | 29.72 | |||||
| 6-1 Month Momentum % | 70.34 | |||||
| 12-1 Month Momentum % | 81.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.03 | |||||
| Quick Ratio | 0.56 | |||||
| Cash Ratio | 0.09 | |||||
| Days Inventory | 234.68 | |||||
| Days Sales Outstanding | 80.34 | |||||
| Days Payable | 152.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.05 | |||||
| Dividend Payout Ratio | 0.19 | |||||
| Forward Dividend Yield % | 0.05 | |||||
| 5-Year Yield-on-Cost % | 0.05 | |||||
| 3-Year Average Share Buyback Ratio | -2.7 | |||||
| Shareholder Yield % | 1.2 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 59.89 | |||||
| Operating Margin % | 6.49 | |||||
| Net Margin % | 0.53 | |||||
| FCF Margin % | 3.39 | |||||
| ROE % | 0.58 | |||||
| ROA % | 0.3 | |||||
| ROIC % | 0.6 | |||||
| 3-Year ROIIC % | -4.08 | |||||
| ROC (Joel Greenblatt) % | 10.2 | |||||
| ROCE % | 7.05 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 583.29 | |||||
| Forward PE Ratio | 50.74 | |||||
| PE Ratio without NRI | 389.54 | |||||
| PS Ratio | 3.38 | |||||
| PB Ratio | 3.7 | |||||
| Price-to-Tangible-Book | 7.84 | |||||
| Price-to-Free-Cash-Flow | 97.26 | |||||
| Price-to-Operating-Cash-Flow | 28.32 | |||||
| EV-to-EBIT | 44.48 | |||||
| EV-to-EBITDA | 22.18 | |||||
| EV-to-Revenue | 3.89 | |||||
| EV-to-FCF | 114.83 | |||||
| Price-to-Graham-Number | 11.65 | |||||
| Earnings Yield (Greenblatt) % | 2.25 | |||||
| FCF Yield % | 1 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Piramal Pharma Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 86,390.7 | ||
| EPS (TTM) (₹) | 0.38 | ||
| Beta | 0 | ||
| Volatility % | 29.66 | ||
| 14-Day RSI | 29.72 | ||
| 14-Day ATR (₹) | 11.771371 | ||
| 20-Day SMA (₹) | 253.3075 | ||
| 12-1 Month Momentum % | 81.1 | ||
| 52-Week Range (₹) | 115.1 - 307.85 | ||
| Shares Outstanding (Mil) | 1,319.83 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Piramal Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Piramal Pharma Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Piramal Pharma Ltd Frequently Asked Questions
What is Piramal Pharma Ltd(BOM:543635)'s stock price today?
The current price of BOM:543635 is ₹221.65. The 52 week high of BOM:543635 is ₹307.85 and 52 week low is ₹115.10.
When is next earnings date of Piramal Pharma Ltd(BOM:543635)?
The next earnings date of Piramal Pharma Ltd(BOM:543635) is .
Does Piramal Pharma Ltd(BOM:543635) pay dividends? If so, how much?
The Dividend Yield %  of Piramal Pharma Ltd(BOM:543635) is 0.05% (As of Today), Highest Dividend Payout Ratio of Piramal Pharma Ltd(BOM:543635) was 0.19. The lowest was 0. And the median was 0. The  Forward Dividend Yield % of Piramal Pharma Ltd(BOM:543635) is 0.05%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers